References
- Australian Society for HIV Medicine. (2009). An overview of hepatitis C: Clinical management in the opiate pharmacotherapy setting. Canberra, ACT: Commonwealth of Australia.
- Batey, R. (2003). Chronic hepatitis C: An update. Australian Family Physician, 32, 795–834.
- Bonkovsky, H. & Mehta, S. (2001). Hepatitis C: A review and update. Journal of the American Academy of Dermatology, 44, 159–179.
- Buti, M., San Miguel, R., Brosa, M., Canases, J., Medina, M., Casado, M., Fosbrook, L., & Esteban, R. (2005). Estimating the impact of hepatitis C virus therapy on future liver related morbidity, mortality and costs related to chronic hepatitis C. Journal of Hepatology, 42, 639–645.
- Commonwealth Department of Health and Ageing. (2005). National Hepatitis C Strategy 2005–2009. Canberra: Commonwealth of Australia.
- Doab, A., Treloar, C., & Dore, G. J. (2005). Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injecting drug users in Australia. Clinical Infectious Diseases, 40(Suppl. 5), 313–320.
- Dore, G. ( Ed.) (2001). Initial assessment and clinical monitoring of people with hepatitis C. Melbourne, VIC: IP Communications.
- Ebner, N., Wanner, C., Winklbaur, B., Matzenauer, C., Jachmann, C., Thau, K., & Fischer, G. (2009). Retention rate and side effects in a prospective trial of hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid dependent patients. Addiction Biology, 14(2), 227–237.
- Freedman, K. & Nathanson, J. (2009). Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders. Expert Review of Anti-infective Therapy, 7(3), 363–376.
- Gidding, H., Topp, L., Middleton, M., Dore, G., Robinson, K., Maher, L., Kaldor, J. M., Dore, G. J., & Law, M. G. (2008). The epidemiology of hepatitis C in Australia—a review of notifications, treatment uptake and associated liver transplantations 1997–2006. Journal of Gastroenterology and Hepatology, 23(Suppl. 6), A378–A382.
- Grebely, J., Genoway, K., Raffa, J., Dhadwal, G., Rajan, T., Showler, G., Kalousek, K., Duncan, F., Tyndall, M. W., Fraser, C., Conway, B., & Fischer, B. (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93, 141–147.
- Matthews, G., Kronborg, I., & Dore, G. (2005a). Treatment for hepatitis C infection among current injection drug users in Australia. Clinical Infectious Diseases, 40, S325–S329.
- Matthews, G., Kronborg, I., & Dore, G. (2005b). Treatment for hepatitis C virus infection among current injection drug users in Australia. Clinical Infectious Diseases, 40, S325.
- McNally, S., Temple-Smith, M., & Pitts, M. (2004). Making decisions about hepatitis C treatment. Melbourne, VIC: La Trove University.
- National Centre for HIV Epidemiology and Clinical Research. (2009). Australian NSP survey national data report 2004–2008. Sydney, NSW: University of New South Wales.
- National Health and Medical Research Council. (2001). Australian alcohol guidelines: Health risks and benefits. Canberra, ACT: Commonwealth of Australia.
- National Institutes of Health. (2002). Managing hepatitis C: 2002. Bethesda, MD: US Department of Health and Human Services.
- Nguyen, O., Dore, G., Kaldor, J., & Hellard, M. (2007). Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study. International Journal of Drug Policy, 18, 447–451.
- Sylvester, D. L. (2005). Treating hepatitis C virus infection in active substance abusers. Clinical Infectious Diseases, 40(Suppl. 5), 321–324.
- Treloar, C. & Fraser, S. (2009). Hepatitis C treatment in pharmacotherapy services: Increasing treatment uptake needs a critical review. Drug and Alcohol Review, 28, 436–440.
- World Health Organisation. (2000). Hepatitis C factsheet 164. Retrieved March 21, 2008 from http:/www.who.int/inf-fs/en/fact164.html.